Seventeen-year-old varsity basketball player demonstrates mind over matter in battling life-altering setbacks.

Mia Cassella told Newsweek: "Cancer might take away things like my hair or my energy, but it couldn't take away my passion for lifting and working out." ...

The FDA has approved a new three-drug combination to treat certain types of an aggressive blood cancer called large B-cell lymphoma (LBCL).

The FDA has approved Adcetris (brentuximab vedotin) for use in combination with lenalidomide and rituximab to treat patients with relapsed/refractory LBCL after 2 or more lines of systemic therapy who ...

NEW YORK - Pfizer Inc. (NYSE: NYSE:PFE), a pharmaceutical giant with $63.6 billion in annual revenue and an impressive 74% gross profit margin, has announced the U.S. Food and Drug Administration's ...

New York–based hematologist-oncologist and clinical researcher works to lower the barriers to enrolling in clinical trials.

Among older adults with classical Hodgkin lymphoma, frontline N-AVD has been found to be highly effective and well-tolerated.

Here is a select list of cancer therapies approved by the FDA throughout the month of January, featuring patient populations ...

Ann LaCasce, MD, MMSc, delved into some of the most recent advances in the lymphoma space, exploring how these new therapies ...

This is probably because these patients frequently require multiple and prolonged cycles of chemo. People treated for ovarian cancer (32%) and lymphoma (36%) had the lowest risk. Researchers said ...

Panelists discuss the findings from the POLARIX study, focusing on the efficacy and safety of polatuzumab vedotin in combination with rituximab and chemotherapy for untreated diffuse large B-cell ...